AMBIVALENT LTD

Company number 13154457 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

AMBIVALENT LTD - Analysis Report

Company Number: 13154457

Analysis Date: 2025-07-29 12:07 UTC

Financial Health Assessment of AMBIVALENT LTD


1. Financial Health Score: C

Explanation:
AMBIVALENT LTD demonstrates some foundational financial stability with positive net assets and consistent filing compliance. However, the company exhibits symptoms of financial distress such as ongoing losses, minimal turnover, and very low liquidity. These indicators suggest early-stage challenges in generating sustainable revenue and managing expenses. The overall health is fair but requires attention to avoid deterioration.


2. Key Vital Signs

Metric Value (2024) Interpretation
Turnover (Revenue) £100 Extremely low revenue, declining from £300 in prior year; signs of weak sales or market traction.
Profit / (Loss) for Period -£578 Operating loss indicates the company is spending more than it earns, symptomatic of distress.
Fixed Assets £693 Small asset base, but increased compared to prior year, may indicate investment in equipment or resources.
Current Assets £55 Very low current assets suggest limited liquid resources to cover short-term obligations.
Net Current Assets £55 Positive but marginal working capital; limited buffer for operational needs.
Net Assets (Equity) £748 Small but positive equity base showing some retained value in the company.
Share Capital £1 Minimal paid-up share capital, typical for micro-entity startups.
Average Number of Employees 1 Very small workforce, consistent with micro-entity status.

Additional Notes:

  • No current liabilities reported, which is positive for liquidity but may also suggest limited business activity or credit use.
  • Depreciation (~£78) suggests some tangible asset investment but adds to expenses reducing profitability.
  • Company changed name recently (from HAZENT LTD to AMBIVALENT LTD), which might indicate rebranding or strategic shifts.

3. Diagnosis

AMBIVALENT LTD is at an early developmental stage with the financial "vitals" showing limited operational scale and ongoing losses. The very low turnover and negative profit reveal symptoms of insufficient revenue generation and cost control challenges. The company’s fixed assets have increased, suggesting some investment in infrastructure or equipment, but this has not yet translated into improved sales or profitability.

The positive net assets and lack of liabilities are reassuring signs that the company has not overextended itself financially, but the very tight working capital indicates a fragile liquidity position. This "cash flow" situation is precarious—there is barely enough short-term resource to cover immediate needs, akin to a patient with borderline hydration levels.

The single director and sole shareholder structure suggests a closely controlled business with limited external funding, which can be both a strength (agility) and a risk (resource constraints). The micro-entity classification limits reporting requirements but also reflects a small operational footprint.

Overall, the financial health is fragile. The company is not yet generating sustainable income to cover its expenses, and there is a risk that without strategic intervention, it could face worsening losses and cash shortages.


4. Recommendations

Immediate Actions:

  • Boost Revenue Generation: Focus on marketing, sales channels, or partnerships to increase turnover from the current low base. Explore monetising existing assets or diversifying revenue streams aligned with their industry (performing arts, video production, retail).

  • Cost Management: Review all expenses critically to reduce unnecessary costs especially "Other charges" which amount to £575, a significant burden on low turnover.

  • Cash Flow Monitoring: Implement rigorous cash flow forecasts and controls to ensure the company can meet short-term obligations without stress.

  • Capital Injection: Consider raising additional capital or securing short-term financing to improve liquidity and support growth initiatives.

  • Strategic Review: Given the recent name change, reassess the business model and market positioning to ensure alignment with market demand and long-term viability.

Medium-Term Actions:

  • Financial Reporting & Analysis: Develop more detailed financial tracking to identify profit centers and loss drivers.

  • Build Reserves: Aim to accumulate retained earnings to create a buffer against future downturns.

  • Explore Grants or Support: Investigate eligibility for grants or government support especially relevant to creative industries and SMEs.


Perspective: Financial Health Diagnostician · Model: gpt-4.1-mini · Generated 29 July 2025

Sign in to generate a free AI analysis of this company — no password needed, just an email link.